Regeneron and Sanofi have expanded their 17-year collaboration to co-develop and co-commercialize four new long-acting antibodies targeting inflammatory pathways, with Sanofi paying Regeneron $1.0 billion upfront and up to $7.0 billion in milestone payments. The deal reshapes how the two companies will develop and profit from Regeneron-invented assets, and resolves a dispute over Sanofi’s disclosure obligations on their existing blockbuster Dupixent.
Under the Sixth Amendment to their Antibody License and Collaboration Agreement, Regeneron will lead development and U.S. regulatory strategy for four new products: antibodies targeting interleukin-13, interleukin-4, IL-4 receptor alpha, and a bispecific antibody targeting IL-4 by IL-13. Regeneron also holds options to add Sanofi’s Phase 2/3 asset lunsekimig and another early-stage Sanofi program to the collaboration, reimbursing Sanofi for development costs if it exercises those options. Development costs for all products under the collaboration will be split equally between the parties, except that Regeneron bears any spending above an agreed budget cap. Global profits on the new products will be divided equally. Sanofi takes the lead on commercialization outside the United States and globally for marketing approval outside the U.S.
What it means
The deal represents a significant capital inflow for Regeneron in a year when the company’s revenue growth has stalled. FY2025 revenue grew just 1.0 percent, suggesting that Regeneron’s marketed portfolio is not expanding at a pace to offset patent cliffs or market saturation. The $1.0 billion upfront payment provides immediate cash, while the $7.0 billion in potential milestones creates a revenue stream contingent on clinical and commercial success of assets still in development. The equal profit-share structure differs from typical licensing deals where the licensor takes a royalty; here, Regeneron shares both development risk and upside, which suggests confidence in these assets but also signals that Sanofi’s commercial reach and resources are material to their value.
The settlement of Regeneron’s lawsuit over Dupixent disclosure and audit rights is the deal’s other material element. The filing does not disclose the terms of the settlement, so it is unclear whether Regeneron extracted concessions on transparency or simply traded the lawsuit for the new collaboration terms. The resolution removes a source of friction between the parties and likely signals that Regeneron accepted Sanofi’s position in exchange for the expanded pipeline and upfront cash.
The filing also flags an acquired in-process research and development charge of approximately $22 million pre-tax in Q3 2026, reducing both GAAP and non-GAAP net income per diluted share by approximately $0.18. This is a one-time accounting charge related to the transaction and does not reflect operational performance.
What to watch
The next disclosure point is Regeneron’s Q3 2026 earnings report, where the company will finalize results and provide updated full-year guidance. The key question is whether this deal signals a shift in Regeneron’s growth strategy toward partnerships on earlier-stage assets, or whether it reflects a temporary capital need. Watch for any commentary on the development timeline for the four new products and whether Regeneron raises revenue or earnings guidance to reflect the $1.0 billion inflow and the probability-weighted value of the $7.0 billion milestone pool.
Source: the company’s 8-K filed 2026-10-06 with the SEC.
